The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials

Patricia M. Plezia, David S. Alberts, Yei Mei Peng, Min Jian Xu, Susan Sayers, Thomas P. Davis, Earl A. Surwit, Frank L. Meyskens

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The design and interpretation of chemoprevention trials are challenging tasks. Innovative methodological approaches to these investigations are in initial stages of development. Important pharmacologic issues should be addressed as early as possible in these trials to facilitate the optimal design of large, Phase III, randomized trials. These include determining the optimal dose of the compound and the toxicity profile. Other key areas involve the use of serum concentrations to monitor subject compliance, the evaluation of concentration of the chemopreventive agent in the target tissue, adequate assessment of the drug delivery systems, and the evaluation of the relationship between the dose administered and the serum or tissue concentrations achieved. Whenever possible the investigation of the relationship between serum or tissue concentrations of a chemopreventive agent vs its biologic activity should be determined. Specific examples involving the retinoids and carotenoids are presented.

Original languageEnglish (US)
Pages (from-to)680-687
Number of pages8
JournalPreventive Medicine
Volume18
Issue number5
DOIs
StatePublished - Sep 1989

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Fingerprint

Dive into the research topics of 'The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials'. Together they form a unique fingerprint.

Cite this